We developed and validated a nomogram to predict the likelihood of MV requirement in patients receiving HFNC therapy. The nomogram may serve as a practical clinical tool to assist physicians in determining whether to continue HFNC therapy or initiate MV in clinically ill patients.
Liu et al. (Thu,) studied this question.